Sign up
Pharma Capital

Ceapro to begin clinical trials for beta glucan to treat high cholesterol

Ceapro Inc (CVE: CZO) CEO Gilles Gagnon tells Proactive Investors the company will soon begin enrollment in clinical trials of its cholesterol-fighting beta glucan.

Meanwhile, the Canadian-based biotech company's recent positive findings indicate its PGX Technology can be used as a delivery system for use on the skin or as a fast-acting oral drug.


View full CZO profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.